Imago BioSciences, Inc.
Imago BioSciences, Inc. (IMGO): 1 pipeline candidate · ~44 mo cash runway · 2 clinical trials. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
43.8 months
0% dilution
Lead: Phase 2
1 candidate
N/A
N/A
A transparent, data-derived signal for Imago BioSciences, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
—
Cash
$7.3M
Quarterly Burn
$11.7M
Runway
43.8 mo
Revenue
—
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (1 candidate)
| Drug | Phase |
|---|---|
| bomedemstat | Phase 2 |
Frequently asked questions
How many drug candidates are in Imago BioSciences, Inc.'s pipeline?
Imago BioSciences, Inc. (IMGO) has 1 pipeline candidate tracked by BioSniper across SEC filings and clinical trial registrations.
What is Imago BioSciences, Inc.'s lead drug candidate?
Imago BioSciences, Inc.'s most advanced tracked candidate is bomedemstat (Phase 2) for Polycythemia Vera; Essential Thrombocythemia.
What is Imago BioSciences, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Imago BioSciences, Inc. has approximately 43.8 months of cash runway.
Who is the CEO of Imago BioSciences, Inc.?
Cirius Therapeutics is the chief executive officer of Imago BioSciences, Inc. (IMGO).
Get the full picture on Imago BioSciences, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.